Studies have shown that patients with CTNNB1 mutant HCC may respond better to certain treatments, and the role of CTNNB1 in HCC helps develop targeted therapies aimed at inhibiting the Wnt/β-catenin signaling pathway. Here, CTNNB1 is linked to hepatocellular carcinoma.